BML-190 (Indomethacin morpholinylamide), CB2 receptor inverse agonist (ab143353)

Overview

  • Product name

    BML-190 (Indomethacin morpholinylamide), CB2 receptor inverse agonist
  • Description

    Selective CB2 receptor inverse agonist
  • Biological description

    Selective CB2 receptor inverse agonist (Ki = 435 nM). Reduces LPS-induced NO and IL-6 production. Inhibits LPS-induced PGE2 production and COX-2 induction.
  • CAS Number

    2854-32-2
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-1-morpholin-4-ylethanone
  • Molecular weight

    426.89
  • Molecular formula

    C23H23ClN2O4
  • PubChem identifier

    2415
  • Storage instructions

    Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in DMSO to 50 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    C(CC1=C(N(C2C=CC(=CC1=2)OC)C(C3C=CC(=CC=3)Cl)=O)C)(N4CCOCC4)=O
  • Source

    Synthetic

  • Research areas

References

This product has been referenced in:

  • Zhang Q  et al. In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes. Eur J Pharm Sci 41:163-72 (2010). Read more (PubMed: 20542112) »
  • New DC & Wong YH BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett 536:157-60 (2003). Read more (PubMed: 12586356) »
  • Klegeris A  et al. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139:775-86 (2003). Read more (PubMed: 12813001) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab143353.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up